

Synthesis and characterization of some new N-mannich bases for clonazepam

Maha S. H. Alnuaimi , Khalaf F Alsamarrai , Athraa Aameed jassim*

*Chemistry Department, College of Education, University of Samarra

Keywords: N-mannich bases, Clonazepam

Received (April) , **Accepted** (June).

Abstract:

The N- Mannich bases (1-10) have been synthesized by reaction of clonazepam with formaldehyde or benzaldehyde and different secondary amines. The N-Mannich bases were subjected to physicochemical studies like melting point determination, TLC and yield%. The structures of mannich bases were characterized by IR, ¹HNMR and ¹³CNMR spectroscopy.

تحضير وتشخيص بعض N- قواعد ماننيخ الجديدة للكلونازيبام
مها صالح حسين النعيمي * خلف فارس السامرائي * عذراء حميد جاسم
 *قسم الكيمياء/كلية التربية/جامعة سامراء


الخلاصة :

تم في هذا البحث تحضير N- قواعد ماننيخ (1-10) للكلونازيبام من تفاعله مع الفورمالديهايد او البنزليديهايد وامينات ثانوية مختلفة . تم اثبات وتشخيص التراكيب المحضرة بالطرائق الفيزيائية مثل تعين درجة الانصهار , تقنية الـ TLC ونسبة المنتج وباستعمال الطرائق الطيفية (طيف الاشعة تحت الحمراء , طيف الرنين النووي المغناطيسي للبروتون والكربون 13) .

الكلمات المفتاحية: N- قواعد ماننيخ , كلونازيبام

Introduction

The scientific name of Clonazepam ^[1] is 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one. It is medication of the benzodiazepine class. It concedes a derivative of nitrazepam and its structural formula as below ^[2,3]:




Clonazepam is given for the management of panic^[4], depression^[5], sleep- associated movements^[6] and epilepsy disorders^[7]. It has anti-anxiety, sedative, relaxant of muscle, against convulsion and sleepiness properties^[8]. The elimination of its plasma half-life range from 18–50 hours to 19–60 hours, and it is known as to be a long-acting benzodiazepine ^[9]. The profile of pharmacologic action of clonazepam is similar to those other benzodiazepines, ties to particular site on the GABA gamma aminobutyric acid receptor ^[10].

A Mannich base involves a worthy position in the generation of many pharmaceutical products and common compounds in natural products which have aminoalkyl chain. The examples of different therapeutic agents for Mannich bases are tramadol as an analgesic, molindone as a neuroleptic, procyclidine as an antiparkinsonic, ranitidine and triprolidine an antihistaminic agent ^[11-13]. They are known for their broad gamut of


biological activities range from against inflammation ^[14,15], against malaria ^[16], against cancer ^[17,18], against bacteria ^[19,20], against fungi ^[21], against convulsion ^[22], against Helminthic ^[23], and against TB ^[24,25].

N-Mannich bases are prepared through the Mannich reaction, which involves a NH-acidic compound, an aldehyde (usually formaldehyde) and an amine Scheme1.



Scheme1. Equation preparation of N-Mannich bases

The present work involved prepared ten of N-Mannich bases derivatives from clonazepam the compounds (1-10), by condensing NH- group of clonazepam with formaldehyde or benzaldehyde and some secondary amines (dimethyl amine, diethyl amine, piperidine , morpholine and piprazine) scheme 2.



Scheme 2. Recommend Mechanism for Synthesis N-Mannich of clonazepam

Experimental:

Starting materials and reagent were from commercial chemical suppliers. Melting points were determined in open capillary tube and are uncorrected. The IR spectra

(KBr, cm⁻¹) were recorded on Perkin Elmer spectrometer, ¹H NMR and ¹³CNMR (δ, ppm) spectra were recorded on a Bruker 400 MHz spectrometer using TMS as an internal standard and DMSO as a solvent. The purity of compounds and progress of the reaction were checked by TLC using silica gel (60-230) mesh as stationary phase and (ethyl acetate : n-hexane) (1:1) as mobile phase.

Procedure for preparation of N-mannich bases:

Equimolar quantity of Clonazepam, formaldehyde or benzaldehyde and various secondary amines (dimethyl amine, diethyl amine, piperidine, morpholine, piperazine) were dissolved in 20ml methanol, then add 4-5 drops of glacial acetic acid and the mixture was refluxed for (3-8) hours, then the mixture was stirred at room temperature for 24 hours. The precipitates were obtained after several days ageing at 0°C refrigerator, the product was washed with acetone then recrystallized by using ethanol. Completion of reaction was monitored by TLC analysis for several times. Melting point, R_f value and yield were noted. Physical data of various N-Mannich derivatives are shown in table 1.

Table 1 : Physical data of the synthesized compounds (1-10)

Comp. No	Amine	Aldehyde	Mol.formula	Mol.wt	m.p ^o C	%yield	R _f * value
1	Dimethyl amine	formaldehyde	C ₁₈ H ₁₇ ClN ₄ O ₃	372.8	186-188	55	0.88
2	Diethyl amine	formaldehyde	C ₂₀ H ₂₁ ClN ₄ O ₃	400.8	200-201	67	0.68
3	piperidine	formaldehyde	C ₂₁ H ₂₁ ClN ₄ O ₃	412.8	198 dec.	73	0.85
4	morpholine	formaldehyde	C ₂₀ H ₁₉ ClN ₄ O ₄	414.8	192-190	65	0.77
5	piperazine	formaldehyde	C ₂₀ H ₂₀ ClN ₅ O ₃	413.8	240-245	52	0.79
6	Dimethyl amine	benzaldehyde	C ₂₄ H ₂₁ ClN ₄ O ₃	448.9	199-202	44	0.77
7	Diethyl amine	benzaldehyde	C ₂₆ H ₂₅ ClN ₄ O ₃	476.9	177-179	60	0.69
8	piperidine	benzaldehyde	C ₂₇ H ₂₅ ClN ₄ O ₃	488.9	150-152	70	0.78
9	morpholine	benzaldehyde	C ₂₆ H ₂₃ ClN ₄ O ₄	490.9	123-125	54	0.85
10	piperazine	benzaldehyde	C ₂₆ H ₂₄ ClN ₅ O ₃	489.9	180-182	75	0.68

*(ethyl acetate : n-hexane) (1:1)

Results and Discussion

The spectral data reveals that structures of all the synthesized compounds are in good agreement with the proposed ones. The FTIR spectra of compounds show absence of NH band at around 3430 cm⁻¹ for benzodiazepine ring except compounds (5,10) which have piperazine rings. The appearance of signal δ₅- 4.8(s,2H, N-CH₂-N) in ¹H NMR spectra of compounds (1-5) and signal δ (5.9-4.6) (s, 1H) in ¹H NMR spectra of compounds (6-10) reveals the formation of CH₂, CH bridge between clonazepam and secondary amine which supports the formation of N-Mannich bases.

In ¹³C NMR spectra, DEPT-135 of N-Mannich bases (1-5) show negative signal at around δ 69-62 for (N-CH₂-N) bridge beside CH₂ for amine and CH₂ for benzodiazepine ring. The DEPT-90 spectrum of N-Mannich bases (6-10) shows positive signal at around δ 69-62 for CH (N-CH-N) bridge beside CH for aromatic ring. The spectral results of synthesized compounds (1-10) are given in table 2.

Table 2: Spectral data of N- Mannich bases (1-10)

Comp. No	IR (KBr ,cm ⁻¹)	¹ HNMR & ¹³ CNMR (δ ,ppm)
1	3040(CH-Ar),(2970,2835) (CH-aliphatic),1685(C=O), 1620(C=N),(1570,1540) (N=O),1345(C-NO ₂), 1025 (C-N), 730 (Ar-Cl)	¹ HNMR: 2.4(s,3Ha), 4.3 (s,2H, ringHb), 4.8(s,2Hc,N-CH ₂ -N), 7.4-7.5(m,3H, Ar-Hd) , 7.6(s,1H, Ar-He), 7.7(s,1H, Ar-Hf) , 8.3(d,2H,Ar-Hn) ¹³ CNMR : 46.1(N-CH ₃), 56.7(CH ₂ , ring) , 62.2(N-CH ₂ -N)bridge , 141-122(C,Ar), 144(C-NO ₂), , 167.8(C=N) , 169.2 (C=O)
2	3060(CH-Ar), (2940,2890) (CH-aliphatic), 1680 (C=O), 1628 (C=N) , (1580,1543) (N=O),1335(C-NO ₂), 1023 (C-N), 750 (Ar-Cl)	¹ HNMR: 0.8-.1.1(t,6H,CH ₃ ,Ha) , 2.4-2.3(q,4H,CH ₂ , Hb) , 4.3 (s,2H, ringHc), 4.8(s,2Hd,N-CH ₂ -N), 7.4-7.5(m,3H, Ar-He) , 7.6(s,1H, Ar-Hf) , 7.7(s,1H, Ar-Hn) ,8.3(d,2H,Ar-Hh) ¹³ CNMR : 18.1(CH ₃ -N), 48.2(CH ₂ -N) , 56.7(CH ₂ , ring) , 62.2(N-CH ₂ -N)bridge ,141-122(C,Ar), 144(C-NO ₂), 167.8(C=N) , 169.2 (C=O)
3	(3103,3050)(CH- Ar), (2956,2850)(CH-aliphatic), 1693 (C=O), 1612 (C=N), (1529,1519) (N=O),1340(C-NO ₂), 1040 (C-N), 760 (Ar-Cl)	¹ HNMR: 1.03-1.22 (m,6H,CH ₃ ,Ha) , 2.1-2.3(t,4H,CH ₂ , Hb) , piperidine:, 4.31 (s,2H, ringHc) , 5.07(s,2Hd,N-CH ₂ -N),7.4-7.5(m,3H, Ar-He) ,7.6(d,1H, Ar-Hf),7.73-7.74(d,1H, Ar-Hn) ,8.36-8.39(dd,2H,Ar-Hh) ¹³ CNMR : , 25.1 -26(CH ₂ -N) piperidine, 56.7(N-CH ₂), 58.7(CH ₂ , ring) , 62.3(N-CH ₂ -N)bridge , 121.9-141.3 (C,Ar), 144(C-NO ₂), 167.6(C=N) ,168.9(C=O)
4	3103(CH-Ar), (2968,2850) (CH-aliphatic), 1695 (C=O), 1616 (C=N), (1575,1535) (N=O),1338(C-NO ₂), (1163,1099)(C-O-C), 1018(C-N), 730 (Ar-Cl)	¹ HNMR:, 2.7-.3(t,4H,CH ₂ β morpholine, Ha), 3.2-3.5(t,4H,CH ₂ α morpholine, Hb), 4.3(s, 2H, Hc), 4.83(s,2H, N-CH ₂ -N, Hd), 7.4-7.5(m,3H, Ar-He) , 7.6(s,1H, Ar-Hf),7.7(s,1H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 54.08(CH ₂ -N-CH ₂) morpholine, 57.07(CH ₂ , ring) , 60.2(CH ₂ -O-CH ₂) morpholine, 63.1(N-CH ₂ -N)bridge , 122-141(CH,Ar), 144(C-NO ₂),167.8(C=N) , 169.2 (C=O)
5	3420 (N-H) ,3049(CH-Ar), (2927,2860)(CH-aliphatic), 1693(C=O) , 1618 (C=N), (1556,1530) (N=O),1340(C-NO ₂), 1060 (C-N), 734 (Ar-Cl)	¹ HNMR: 1.09 (s,1H,N-Ha) , 2.4-.2.6(t,4H,CH ₂ β piprazine, Hb), 2.8-3.1(t,4H,CH ₂ α piprazine, Hc), 4.3(s, 2H, Hd), 4.81(s,2H, N-CH ₂ -N) bridge, He, 7.4-7.5(m,8H, Ar-Hf) ,7.6-7.7 (s,2H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 52. 9(CH ₂ -N-CH ₂) piprazine, 53. 8(CH ₂ -N-CH ₂) piprazine, 56.8(CH ₂ , ring) , 69.9(N-CH-N)bridge , 119-141(CH,Ar), 144.3(C-NO ₂), 168.1(C=N) , 169.1 (C=O)
6	3107(CH-Ar),2970(CH-aliphatic), 1695 (C=O), 1618 (C=N),(1562,1540) (N=O), 1338(C-NO ₂), 1018 (C-N), 730 (Ar-Cl)	¹ HNMR: 2.4(s,3Ha) , 4.3(s,2H, ringHb) , 4.8(s,1Hc,N-CH-N) bridge, 7.4-7.5(m,8H, Ar-Hd) ,7.6(s,1H, Ar-He), 7.7(s,1H, Ar-Hf),8.3(d,2H,Ar-Hn) ¹³ CNMR : 46.1(N-CH ₃), 56.7(CH ₂ , ring)), 62.2(N-CH-N)bridge , 122-141(C,Ar), 144(C-NO ₂), 167.8(C=N) , 169.2 (C=O)
7	(3105,3020)(CH-Ar), (2973 ,2885)(CH-aliphatic), 1690 (C=O),1618(C=N), (1570 ,1535) (N=O),1337(C-NO ₂), 1020 (C-N), 760 (Ar-Cl)	¹ HNMR: 0.84-1.2(t,6H,CH ₃ ,Ha), 2.1-2.5(q,4H,CH ₂ , Hb) , 4.3(s,2H, ring Hc) , 4.6(s,2Hd,N-CH ₂ -N bridge), 7.3-7.5(m,8H, Ar-He) ,7.6(d,1H, Ar-Hf), 7.7(s,1H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 15.8(CH ₃ -N), 54.07(CH ₂ -N) , 57.07 (CH ₂ , ring) , 62.4(N-CH-N)bridge , 119-141(C,Ar), 144(C-NO ₂), 167.8(C=N) , 169.2 (C=O)
8	(3107,3030)(CH-Ar), (2962 ,2870)(CH-aliphatic), 1685(C=O),1620(C=N), (1573,1537) (N=O),1339(C-NO ₂),(1080,1040)(C-N), 755 (Ar-Cl)	¹ HNMR:, 1.1-.1.3(t,6H,CH ₃ ,Ha), 2.3-2.5(q,4H,CH ₂ , Hb) , 4.3(s,2Hb,N-CH ₂ -N,Hc) , 5.9(s,1H, N-CH-N bridge, Hd), 7.2-7.5(m,8H, Ar-He) , 7.6(s,1H, Ar-Hf), 7.7(s,1H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 18.1(CH ₃ -N), 46.1(N-CH ₂), 49.2(CH ₂ -N) , 56.7(CH ₂ , ring) , 62.2(N-CH-N)bridge , 122-141(C,Ar), 144(C-NO ₂), 167.8(C=N) , 169.2 (C=O)

9	(3109,3050)(CH-Ar), (2983,2840)(CH-aliphatic), 1690 (C=O), 1630 (C=N), (1570,1545) (N=O),1337(C- NO ₂), (1116,1090(C-O-C), 1040 (C-N), 750 (Ar-Cl)	¹ HNMR:, 2.7-3(t,4H,CH ₂ β morpholine, Ha), 3.2-3.5(t,4H,CH ₂ α morpholine, Hb), 4.3(s, 2H, Hc), 4.8(s,2H, N-CH ₂ -N, Hd), 7.4-7.5(m,8H, Ar-He) , 7.6(s,1H, Ar-Hf),7.7(s,1H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 57.07(CH ₂ , ring) , 54.08(CH ₂ -N-CH ₂) morpholine 60.2(CH ₂ -O-CH ₂) morpholine, 63.1(N-CH-N)bridge , 122-141(CH,Ar), 141(C-NO ₂) ,167.8(C=N) , 169.2 (C=O)
10	3427(N-H),3050(CH-Ar), 2927(CH-aliphatic),1710 (C=O),1614(C=N), (1579, 1535) (N=O),1326(C-NO ₂), 1060 (C-N), 750 (Ar-Cl)	¹ HNMR: 1.09 (s,1H,N-Ha) , 2.4-2.6(t,4H,CH ₂ β piprazine, Hb), 2.8-3.1(t,4H,CH ₂ α piprazine, Hc), 4.3(s, 2H, Hd), 5.9(s,1H, N-CH-N bridge, He), 7.4-7.5(m,8H, Ar-Hf) , 7.6-7.7 (s,2H, Ar-Hn) , 8.3(d,2H,Ar-Hh) ¹³ CNMR : 52. 9(CH ₂ -N-CH ₂) piprazine ,53. 8(CH ₂ -N-CH ₂) piprazine, 56.8(CH ₂ , ring) , 69.9(N-CH-N)bridge , 119-141(CH,Ar), 144.3(C-NO ₂) ,168.1(C=N) , 169.1 (C=O)








Fig. 1 ¹HNMR of compound 4

Fig. 2 ^{13}C NMR of compound 4Fig.3 ^{13}C NMR (DEPT135) of compound 4

Fig.4 ^{13}C NMR (DEPT90) of compound 4Fig. 5 ^1H NMR of compound 10




Fig.8 ¹³CNMR (D)

References

1. Shorter E. (2005) Benzodiazepines, **A Historical Dictionary of Psychiatry**, Oxford University Press. : 41–2.
2. **British pharmacopeia**, (2014) stationary office, London: Medicines and Health care products regulatory agency ,(1-2):506-508 and 587-588.
3. **The United states Pharmacopia** ,(2013), USP36,NF 31, 5 : 3052 , 4695.
4. Davidson JRT and Moroz G., (1998) Pivotal studies of clonazepam in panic disorder, **Psychopharmacol Bull**, 34:169-174.
5. Morishita S. and Aoki S. (1999) Clonazepam in treatment of prolonged depression , **J Affect Disord** ,53:275-278.
6. Salelu M.,el al, (2001)Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD):acute placebo-controlled sleep laboratory studies with clonazepam ,**Eur Neuropsychopharmacol**,11:153-161.
7. Rossetti A., Reichhart M., Schaller M. ,Despland P. and Bogousslavsky J.,(2004) Propofol treatment of refractory status epilepticus: a study of 31 episodes, **Epilepsia**, 45 (7): 757–763.
8. Ståhl Y., Persson A., Petters I. , Rane A. , Theorell K., Walson P., Persson P., Rane T. and Walson, (1983) Kinetics of clonazepam in relation to electroencephalographic and clinical effects, **Epilepsia**, 24(2): 225–231.
9. Chouinard G.,Young SN, Annable L., (1983) Antimanic effect of clonazepam, **Biol psychiatry** ,18(4):451-466.

10. Sieghart W.,(1994) Pharmacology of benzodiazepine receptors ,**Psychiatry Neurosci** ,19(1):24-29
11. Michael A.,Bernhard W. and Nikolaus R.,(1998) Review, Modern Variants of the Mannich Reaction ,**Angew. Chem. Int. Ed** ,37:1044-1070.
12. Suman B., Neha S., Anu K., Sunil K. and Vipin S.,(2014) Review Article Mannich Bases: An Important Pharmacophore in Present Scenario, **International Journal of Medicinal Chemistry** :1-15.
13. Gheorghe R.,(2015) Mannich bases in medicinal chemistry and drug design, **European Journal of Medicinal Chemistry**, 89: 743–816.
14. Koksai M., okhan N., upeli E., Yesilada E., and Erdo- gan H.,(2007) Analgesic and anti-inflammatory activities of some new Mannich bases of 5-nitro-2-benzoxazolinones, **Archives of Pharmacal Research**, 30(4): 419–424.
15. Neeraj K., Sharma C. , Ranawat M., Singh H., Chauhan L.,, Dashora N. (2015) Synthesis, analgesic and anti-inflammatory activities of novel mannich bases of benzimidazoles, **Journal of Pharmaceutical Investigation**, 45(1): 65-71.
16. Roy S., Chetia D., Rudrapal M. and Prakash A., (2013) Synthesis and antimalarial activity study of some new Mannich bases of 7-chloro-4-aminoquinoline, **Med Chem.**, 9(3):379-383.
17. Shivarama B., Holla B., Veerendra M., Shivananda K. and Boja P.,(2003) Synthesis characterization and anticancer activity studies on some Mannich bases derived from 1,2,4-triazoles ,**European Journal of Medicinal Chemistry**, 38 (7–8):759–767.
18. Ivanova Y., Momekov G., Petrov O., Karaivanova M., and Kalcheva V., (2007) Cytotoxic Mannich bases of 6-(3-aryl-2-propenoyl)- 2(3H)-benzoxazolones, **European Journal of Medicinal Chemistry**, 42(11) : 1382–1387.
19. Ashok M., Holla B. S., and Poojary B., (2007) Convenient one pot synthesis and antimicrobial evaluation of some new Mannich bases carrying 4-methylthiobenzyl moiety, **European Journal of Medicinal Chemistry**, 42, (8): 1095–1101.
20. Pandeya S., Nath G., and Clercq E. De, (2000) Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases, **European Journal of Medicinal Chemistry**, 35(2) : 249–255.
21. Abrão P., Pizi R., de Souza T., Silva N., Fregnan A., Silva F., Coelho L., Malaquias L., Dias A., Dias D., Veloso M., and Carvalho D.,(2015) Synthesis and Biological Evaluation of New Eugenol Mannich Bases as Promising Antifungal Agents., **Chem Biol Drug Des**,86(4):459-65.
22. Vashishtha S., Zello G., Nienaber K. et al., (2004) Cytotoxic and anticonvulsant aryloxyaryl Mannich bases and related 14 International Journal of Medicinal Chemistry compounds, **European Journal of Medicinal Chemistry**, 39(1): 27–35.
23. Chaluvvaraju K. and Bhat K.,(2011) Studies on the Anthelmintic Property of Aminobenzylated Mannich Bases, **J Young Pharm**, 3(3): 243–245.
24. Sriram D., Banerjee D., and Yogeewari P., (2009) Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities, **Journal of Enzyme Inhibition and Medicinal Chemistry**, 24(1): 1–5.
25. Mulla J., Khan A., Panchamukhi S., Khazi M., Kalashetti M., and Khazi I., (2011) Synthesis and antitubercular activity of Mannich bases of imidazo [2,1-b] [1,3,4] thiadiazoles, **Indian Journal of Novel Drug Delivery**, 3(4): 289–295.